Brand vs Compounded Semaglutide: Is the Price Gap Worth It?
Brand Wegovy lists near $1,349/month; compounded semaglutide runs $119-299. The gap buys FDA approval, trial evidence, and manufacturing oversight — real value some patients need and others can forgo.
- Brand Wegovy: ~$1,349 list, ~$349 NovoCare self-pay, as low as ~$25 insured copay.
- Compounded semaglutide: ~$145-299/month cash, but not FDA-approved.
- The gap buys FDA review, STEP/SELECT trial evidence, and manufacturing consistency.
- If insured, brand often wins on price too; uninsured, compounded is usually cheaper.
The price gap
Brand Wegovy lists near $1,349 per 28 days. Compounded semaglutide runs roughly $145 to $299 per month. On sticker price, compounded wins by a wide margin. But list price is rarely what a brand patient pays: NovoCare self-pay brings Wegovy to about $349 per month, and an insured copay with a savings card can fall to about $25.
So the real comparison depends entirely on your insurance. Priced correctly, the gap can be enormous or nearly closed.
What the gap buys
The price difference is not arbitrary. Brand semaglutide is FDA-approved, meaning it passed review for safety, effectiveness, and manufacturing quality. It carries the STEP and SELECT trial evidence directly. Every vial is manufactured to a consistent specification.
Compounded semaglutide has none of these. It is not FDA-approved, the FDA does not verify it before marketing, and it carries no formulation-specific trial evidence. That is the trade-off for the lower price — not necessarily a dealbreaker, but a real difference a patient should understand.
| Option | Monthly | FDA-approved? | Trial evidence |
|---|---|---|---|
| Insured Wegovy copay | ~$25 | Yes | Yes (STEP/SELECT) |
| Compounded semaglutide | $145–299 | No | No |
| Wegovy NovoCare self-pay | ~$349 | Yes | Yes |
| Wegovy list | ~$1,349 | Yes | Yes |
If you have insurance
For an insured patient whose plan covers Wegovy, brand often wins on both price and safety. A $25 copay undercuts every compounded option and delivers the approved product. The obstacle is coverage: many plans require prior authorization and a documented obesity diagnosis, and Medicare excludes weight-loss GLP-1s under current law.
Check your copay first. If it exists, the brand-versus-compounded question often answers itself in favor of brand.
| Feature | Brand | Compounded |
|---|---|---|
| FDA approval | Yes | No |
| Trial evidence | Yes | No |
| Manufacturing review | Yes | No |
| Lower cash price | No | Yes |
If you are paying cash
Uninsured, the math shifts. Compounded semaglutide at $145 to $299 is substantially cheaper than brand self-pay at $349, and for many cash-pay patients that difference determines whether treatment is affordable at all. The decision becomes whether the savings justify a non-FDA-approved product.
There is no universal answer. A patient who values the approval and trial backing may choose brand self-pay; one for whom cost is the binding constraint may reasonably choose compounded from a verified, licensed pharmacy. A prescriber should guide the choice.
Frequently asked questions
Is compounded semaglutide as good as Wegovy?
It contains semaglutide but is not FDA-approved and has no formulation-specific trial evidence. Whether it is 'as good' cannot be assumed; the approved product has the evidence behind it.
Why is brand so much more expensive?
Brand price reflects FDA approval, trial development, and manufacturing oversight. Compounded skips those, which is why it is cheaper and also why it lacks their guarantees.
Which should I choose?
If insured with coverage, brand often wins on price and safety. Uninsured, compounded is usually cheaper. A clinician should guide the decision.
Sources
- FDA — human drug compounding and GLP-1 status.
- NovoCare and manufacturer pricing, captured September 2026.
- Clinical trials via NEJM (STEP, SELECT, SURMOUNT, SURPASS).
The numbers behind this page
The semaglutide price range, stated precisely
Standard-dose compounded semaglutide runs $119 to $299 a month across the 12 programmes we can price, with a median of $198. The spread between cheapest and dearest is $166 a month, or $1,992 across a year, for a molecule that is chemically identical in every case.
The cheapest verified figure is NexLife at $119 on its 12-month plan; Oak Longevity follows at $133. Half the market sits below $198 and half above it, which makes the median a more useful reference point than the cheapest figure when judging whether a quote is reasonable.
2 programmes additionally advertise a semaglutide microdose, the cheapest at $145 a month. Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
How semaglutide is kept current
The semaglutide figures on this page span $119 to $299 a month across 12 programmes. Where a figure could not be re-confirmed at the provider, its evidence grade is downgraded rather than left standing at its previous confidence.
Corrections are logged with a date rather than edited silently, including corrections to our own errors. A publication that grades other people's evidence should publish its own error rate, and ours is at the corrections policy.
No provider pays for placement, position or inclusion here. Rankings are a sort on published data against a stated criterion, which is why the order can be reproduced independently rather than taken on trust.
Reading the price against the market
Why the spread is this wide
Standard-dose semaglutide spans $119 to $299 a month across 12 programmes we can price, a spread of $180.
The molecule is chemically identical across every programme in the range. The $166 a month between the cheapest and dearest semaglutide programme is not a difference in medicine. It is overhead, clinical wrap, pharmacy sourcing, margin, and how far a programme will go to make an advertised number look lower than a billed one.
Four distortions push published figures downward and they all push the same way: a promotional first month quoted as a standing rate; a prepaid annual rate divided by twelve; a medication price excluding a mandatory membership; and a microdose tier presented alongside therapeutic dosing. Each is individually defensible and together they compound.
Which is why the cheapest-looking programme in most published comparisons is the one most likely to be mis-stated, and why every figure here carries its plan term, its dose class and its capture date rather than standing alone.
Why the spread is this wide
Standard-dose semaglutide spans $119 to $299 a month across 12 programmes we can price, a spread of $180.
The molecule is chemically identical across every programme in the range. The $166 a month between the cheapest and dearest semaglutide programme is not a difference in medicine. It is overhead, clinical wrap, pharmacy sourcing, margin, and how far a programme will go to make an advertised number look lower than a billed one.
Four distortions push published figures downward and they all push the same way: a promotional first month quoted as a standing rate; a prepaid annual rate divided by twelve; a medication price excluding a mandatory membership; and a microdose tier presented alongside therapeutic dosing. Each is individually defensible and together they compound.
Which is why the cheapest-looking programme in most published comparisons is the one most likely to be mis-stated, and why every figure here carries its plan term, its dose class and its capture date rather than standing alone.
Questions this page answers
Why is microdosed semaglutide cheaper?
Because it is less medicine. 2 programmes advertise a semaglutide microdose, the cheapest at $145 a month. A microdose sits below every dose studied in the pivotal trials, so it is not a cheaper route to the result those trials measured.
What is the cheapest compounded semaglutide?
NexLife at $119 a month at a standard therapeutic dose on the 12-month plan ($1,428 total), captured 2026-09-04. 3-month $132; 6-month $125; month-to-month $139. No membership fee, flat at every covered dose. Verified. The next-cheapest is Oak Longevity at $133 (flat, no subscription; not available in California; Provider Reported).
What does compounded semaglutide normally cost?
$119 to $299 a month across 12 programmes, with a median of $198. Half the market sits either side of that median, which makes it a better reference than the cheapest figure when judging a quote.
Does compounded semaglutide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.